Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux

PARIS--(BUSINESS WIRE)-- Regulatory News:

Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30^th 2021:

- 448,434 shares
- € 33,899.60

- Number of executions on buy side on semester: 255
- Number of executions on sell side on semester: 222
- Traded volume on buy side on semester: 269,935 shares for € 99,624.74
- Traded volume on sell side on semester: 251,351 shares for € 96,727.03

As a reminder:

• the following resources appeared on the last half year statement on 31 December 2021 on the liquidity account:

- 429,850 shares
- € 36,891.92

- Number of executions on buy side on semester: 256
- Number of executions on sell side on semester: 155
- Traded volume on buy side on semester: 357,510 shares for € 179,383.26
- Traded volume on sell side on semester: 221,580 shares for € 115,071.34

• the following resources appeared on the liquidity account when the activity started:

- 87,612 shares
- € 196,423.24

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platON is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe in combination with other treatment modalities in difficult-to-treat solid tumors.

OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).

APPENDIX

	Buy Side				Sell Side
	Number of executions	Number of shares	Traded volume in EUR		Number of executions	Number of shares	Traded volume in EUR
Total	255	269,935	99,624.74		222	251,351	96,727.03
03/01/2022	-	-	-		2	10,000	4,400.00
04/01/2022	3	5,000	2,200.00		1	5,000	2,250.00
05/01/2022	2	5,000	2,150.00		-	-	-
06/01/2022	2	5,000	2,100.00		-	-	-
07/01/2022	-	-	-		14	7,267	3,124.81
10/01/2022	2	4,193	1,761.06		-	-	-
11/01/2022	6	5,807	2,497.01		3	12,733	5,602.52
12/01/2022	1	4,645	1,997.35		-	-	-
13/01/2022	3	7,786	3,347.98		1	5,000	2,200.00
17/01/2022	1	2,569	1,078.98		-	-	-
20/01/2022	1	5,000	2,050.00		-	-	-
24/01/2022	3	5,000	2,000.00		1	1	0.42
25/01/2022	-	-	-		2	5,000	2,050.00
28/01/2022	2	1,443	577.20		-	-	-
31/01/2022	1	1	0.40		2	2,894	1,215.48
01/02/2022	1	3,556	1,422.40		-	-	-
03/02/2022	-	-	-		1	2,133	874.53
09/02/2022	3	625	243.75		-	-	-
10/02/2022	6	4,376	1,706.64		1	1	0.40
11/02/2022	1	1	0.40		1	1	0.40
16/02/2022	1	1	0.40		1	1	0.40
21/02/2022	4	10,000	3,800.00		1	1	0.38
22/02/2022	4	5,000	1,800.00		5	1,529	565.73
23/02/2022	-	-	-		10	3,471	1,284.27
24/02/2022	13	15,235	5,332.25		-	-	-
25/02/2022	2	4,765	1,572.45		9	6,071	2,064.14
28/02/2022	-	-	-		7	8,929	3,125.15
01/03/2022	3	2,410	819.40		8	25,000	9,250.00
02/03/2022	4	4,362	1,570.32		2	301	114.38
03/03/2022	-	-	-		1	1	0.38
04/03/2022	10	18,475	6,281.50		-	-	-
07/03/2022	13	15,000	4,800.00		-	-	-
08/03/2022	-	-	-		2	5,000	1,650.00
09/03/2022	-	-	-		7	18,860	6,789.60
11/03/2022	1	5,000	1,700.00		-	-	-
15/03/2022	1	1	0.35		2	2,001	720.36
16/03/2022	1	1	0.35		1	2,000	740.00
17/03/2022	2	2,001	720.36		1	1	0.36
18/03/2022	4	2,122	742.70		2	2,000	740.00
22/03/2022	-	-	-		4	2,000	740.00
23/03/2022	3	2,001	720.36		1	1	0.37
24/03/2022	7	2,001	720.36		5	2,001	720.36
28/03/2022	2	555	194.25		3	2,000	720.00
29/03/2022	4	2,000	720.00		1	100	37.00
30/03/2022	2	180	63.00		-	-	-
31/03/2022	1	1,265	442.75		5	2,001	740.37
01/04/2022	-	-	-		20	29,899	11,959.60
04/04/2022	2	930	372.00		2	4,000	1,720.00
05/04/2022	-	-	-		4	4,000	1,720.00
06/04/2022	3	4,000	1,720.00		6	8,000	3,440.00
07/04/2022	3	4,000	1,640.00		4	3,842	1,652.06
08/04/2022	6	8,000	3,360.00		-	-	-
11/04/2022	-	-	-		1	2,000	840.00
12/04/2022	1	1	0.41		1	1	0.41
13/04/2022	4	6,615	2,579.85		3	2,000	800.00
14/04/2022	4	6,000	2,280.00		-	-	-
19/04/2022	1	2,000	760.00		1	2,000	780.00
20/04/2022	3	2,000	760.00		3	6,000	2,340.00
22/04/2022	1	1	0.39		4	2,838	1,135.20
25/04/2022	3	2,000	780.00		-	-	-
26/04/2022	2	127	49.53		2	1,164	465.60
27/04/2022	3	3,875	1,511.25		1	1	0.39
28/04/2022	5	2,001	760.38		1	1	0.38
29/04/2022	2	1,881	695.97		-	-	-
02/05/2022	3	2,120	784.40		2	401	152.38
03/05/2022	-	-	-		2	445	169.10
04/05/2022	2	2,001	720.36		1	1	0.38
05/05/2022	7	5,999	2,099.65		-	-	-
06/05/2022	2	780	273.00		4	4,000	1,440.00
09/05/2022	3	3,220	1,127.00		-	-	-
10/05/2022	1	800	280.00		2	4,000	1,440.00
11/05/2022	-	-	-		5	4,000	1,440.00
12/05/2022	3	3,200	1,120.00		-	-	-
16/05/2022	2	4,000	1,360.00		-	-	-
17/05/2022	-	-	-		2	2,000	700.00
18/05/2022	3	4,000	1,360.00		-	-	-
23/05/2022	-	-	-		1	2,000	700.00
24/05/2022	1	1	0.34		2	2,001	700.35
25/05/2022	6	2,000	680.00		1	1,000	350.00
27/05/2022	1	1	0.34		1	1	0.34
30/05/2022	1	35	11.90		1	2,000	700.00
31/05/2022	1	1	0.35		1	1	0.35
01/06/2022	6	3,965	1,387.75		1	1	0.36
02/06/2022	2	81	28.35		5	2,000	720.00
03/06/2022	1	523	183.05		-	-	-
06/06/2022	1	1	0.35		-	-	-
07/06/2022	1	1	0.36		5	2,029	730.44
08/06/2022	2	3,396	1,188.60		-	-	-
09/06/2022	1	2,000	680.00		-	-	-
10/06/2022	-	-	-		1	1	0.35
13/06/2022	3	2,000	680.00		1	1,999	699.65
14/06/2022	6	4,127	1,444.45		-	-	-
15/06/2022	8	11,873	3,918.09		2	3,767	1,243.11
16/06/2022	3	3,199	1,023.68		2	3,500	1,155.00
17/06/2022	1	801	248.31		4	1,157	381.81
20/06/2022	1	120	38.40		4	4,000	1,320.00
21/06/2022	2	3,880	1,241.60		-	-	-
22/06/2022	1	1	0.33		1	1	0.33
23/06/2022	-	-	-		4	6,000	2,040.00
24/06/2022	3	2,251	742.83		4	3,272	1,112.48
27/06/2022	3	1,284	436.56		3	2,729	955.15
28/06/2022	6	2,716	923.44		-	-	-
29/06/2022	3	753	248.49		-	-	-
30/06/2022	2	2,997	989.01		-	-	-

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005354/en/

Onxeo

Investor Relations

investors@onxeo.com

+33 1 45 58 76 00

Media Relations

Arthur Rouillé

NewCap

onxeo@newcap.eu

+33 1 44 71 94 98

Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh

NewCap

onxeo@newcap.eu

+33 1 44 71 94 92

Certified Adviser for Nasdaq First North

Kapital Partner

www.kapitalpartner.dk

info@kapitalpartner.dk

+45 89 88 78 46

Source: ONXEO